Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

被引：10
|
作者：
Bendell, Johanna C.
Ervin, Thomas J.
Senzer, Neil N.
Richards, Donald A.
Firdaus, Irfan
Lockhart, A. Craig
Cohn, Allen Lee
Saleh, Mansoor N.
Gardner, Lesa R.
Sportelli, Peter
Eng, Cathy
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Sarah Cannon Res Inst Florida Canc Specialists, Englewood, FL USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] Texas Oncol Tyler, Tyler, TX USA
[5] Sarah Cannon Res Inst Oncol Hematol Care Inc, Cincinnati, OH USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Rocky Mt Canc Ctr LLP, Denver, CO USA
[8] Georgia Canc Specialists PC, Sandy Springs, GA USA
[9] Keryx Biopharmaceut Inc, New York, NY USA
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
10.1200/jco.2012.30.18_suppl.lba3501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3501
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [22] RESULTS OF A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL (CORRECT) OF REGORAFENIB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WHO HAVE PROGRESSED AFTER STANDARD THERAPIES
    Yoshino, T.
    Van Cutsem, E.
    Sobrero, A. F.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. -J.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 7 - 7
  • [23] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE III STUDY OF CAPECITABINE/CISPLATIN plus BEVACIZUMAB (BEV) OR PLACEBO (PL) AS 1ST-LINE THERAPY IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER (AGC) (AVAGAST UPDATE)
    van Cutsem, E.
    Shah, M.
    Kang, Y.
    Yamada, Y.
    Yamaguchi, K.
    Nishina, T.
    Doi, T.
    Wu, J.
    Langer, B.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 226 - 226
  • [24] Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study
    Kim, Seung Tae
    Kang, Jung Hun
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Hwang, In Gyu
    Lee, Sang-Cheol
    Park, Keon-Woo
    Lee, Hyo Rak
    Kang, Won Ki
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2822 - 2830
  • [25] Randomized, double-blind, placebo-controlled phase II study of AMG 386 in combination with cisplatin and capecitabine (CX) in patients (pts) with metastatic gastroesophageal adenocarcinoma.
    Eatock, M. M.
    Szanto, J.
    Tebbutt, N. C.
    Bampton, C. L.
    Strickland, A. H.
    Valladares Ayerbes, M.
    Nanayakkara, N.
    Sun, Y.
    Adewoye, A. H.
    Bodoky, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [26] Simvastatin plus capecitabine-cisplatin (XP) versus placebo plus capecitabine-cisplatin (XP) in patients with previously untreated advanced gastric cancer: A double-blind randomized phase 3 study.
    Kim, Seung
    Kang, Won Ki
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Jung Hun
    Hwang, In Gyu
    Lee, Sang-Cheol
    Park, Keon-Woo
    Lee, Hyo Rak
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [28] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF AMG 386 PLUS WEEKLY PACLITAXEL IN PATIENTS (PTS) WITH ADVANCED OVARIAN CANCER
    Vergote, I. B.
    Oza, A. M.
    Hansen, V. L.
    Richardson, G. E.
    Provencher, D. M.
    Ghatage, P.
    Tassoudji, M.
    Sun, Y.
    Stepan, D. E.
    Karlan, B. Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 305 - 306
  • [30] Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study
    Li, Wenhua
    Chang, Jinjia
    Wang, Chenchen
    Peng, Junjie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345